Use of aspirin and bleeding‐related complications after hepatic resection.
Published: 7th February 2018
Authors: M. Gelli, M. A. Allard, O. Farges, C. Paugam‐Burtz, J. Y. Mabrut, J. M. Regimbeau et al.
The operative risk of hepatectomy under antiplatelet therapy is unknown. This study sought to assess the outcomes of elective hepatectomy performed with or without aspirin continuation in a well balanced matched cohort.
Data were retrieved from a multicentre prospective observational study. Aspirin and control groups were compared by non‐standardized methods and by propensity score (PS) matching analysis. The main outcome was severe (Dindo–Clavien grade IIIa or more) haemorrhage. Other outcomes analysed were intraoperative transfusion, overall haemorrhage, major morbidity, comprehensive complication index (CCI) score, thromboembolic complications, ischaemic complications and mortality.
Before matching, there were 118 patients in the aspirin group and 1685 in the control group. ASA fitness grade, cardiovascular disease, previous history of angina pectoris, angioplasty, diabetes, use of vitamin K antagonists, cirrhosis and type of hepatectomy were significantly different between the groups. After PS matching, 108 patients were included in each group. There were no statistically significant differences between the aspirin and control groups in severe haemorrhage (6·5
This observational study suggested that aspirin continuation is not associated with a higher rate of bleeding‐related complications after elective hepatic surgery.Read more
You may also be interested in
Meta‐analysis of delayed gastric emptying after pylorus‐preserving versus pylorus‐resecting pancreatoduodenectomy.
Authors: U. Klaiber, P. Probst, O. Strobel, C. W. Michalski, C. Dörr‐Harim, M. K. Diener et al.
Notes: No difference
Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation.
Authors: G. Vanella, S. Crippa, L. Archibugi, P. G. Arcidiacono, G. Delle Fave, M. Falconi et al.
Notes: Low disease‐related mortality
Authors: P. Studer, T. Horn, A. Haynes, D. Candinas, V. M. Banz
Randomized clinical trial
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. BJS 2018; 105: 192-202.
Authors: T. Ebata, S. Hirano, M. Konishi, K. Uesaka, Y. Tsuchiya, M. Ohtsuka et al.
Notes: No advantage
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Defining the molecular pathology of pancreatic body and tail adenocarcinoma. BJS 2018; 105: e183-e191.
Authors: S. B. Dreyer, N. B. Jamieson, R. Upstill‐Goddard, P. J. Bailey, C. J. McKay, A. V. Biankin et al.
Notes: Worse genetic profile in tail
Randomized clinical trial
Randomized clinical trial of duct‐to‐mucosa versus invagination pancreaticojejunostomy after pancreatoduodenectomy. BJS 2018; 105: 48-57.
Authors: Y. Senda, Y. Shimizu, S. Natsume, S. Ito, K. Komori, T. Abe et al.
Notes: No difference found
Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent.
Authors: X.‐F. Zhang, E. W. Beal, F. Bagante, J. Chakedis, M. Weiss, I. Popescu et al.
Notes: Early recurrence is bad news
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. BJS 2018; 105: 295-301.
Authors: H. Grut, S. Solberg, T. Seierstad, M. E. Revheim, T. S. Egge, S. G. Larsen et al.
Notes: Immunosuppression may not accelerate growth
Authors: K. Mohkam, O. Farges, E. Vibert, O. Soubrane, R. Adam, F.‐R. Pruvot et al.
Notes: Multi‐institutionally validated prognostic tool